Lexicon Pharmaceuticals, INC Form 4 insider transactions

Lexicon Pharmaceuticals, Inc. Director Ivan Cheung has reported the acquisition of 103,806 stock options and 89,312 restricted stock units as part of compensation.

Lexicon Pharmaceuticals, Inc. Director Sam L. Barker has been granted 103,806 stock options and 89,312 restricted stock units, aligning his interests with long-term shareholder value.

Lexicon Pharmaceuticals, Inc. Director Philippe Amouyal was granted 103,806 stock options and 89,312 restricted stock units on June 3, 2025, as part of his compensation.

Lexicon Pharmaceuticals, Inc. Director Raymond Debbane was granted 103,806 stock options and 89,312 restricted stock units on June 3, 2025, as part of his compensation.

Director Judith L. Swain reports a transaction involving Lexicon Pharmaceuticals common stock and restricted stock units on May 13, 2025.

Director Diane E. Sullivan reports acquisition and disposal of Lexicon Pharmaceuticals common stock and restricted stock units on May 13, 2025.

Christopher J. Sobecki, a director at Lexicon Pharmaceuticals, executed transactions involving common stock and restricted stock units on May 13, 2025.

Director Samuel Barker reports acquisition and disposal of Lexicon Pharmaceuticals common stock and restricted stock units on May 13, 2025.

Director Philippe Amouyal reports acquisition of 36,810 shares of Lexicon Pharmaceuticals common stock through vesting of restricted stock units.

Raymond Debbane, a director of Lexicon Pharmaceuticals, reports a transaction involving restricted stock units converting to common stock.

Lisa DeFrancesco, SVP of Investor Relations and Corporate Communications at Lexicon Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units on February 28, 2025.

Kristen Alexander, VP of Finance and Accounting at Lexicon Pharmaceuticals, reports the vesting and subsequent disposal of restricted stock units to cover tax obligations.

Wendy McDermott, SVP of Human Resources at Lexicon Pharmaceuticals, reports the vesting and subsequent disposal of restricted stock units to cover tax obligations.

Alan J. Main, EVP of Innovation & Chemical Sciences at Lexicon Pharmaceuticals, reports the vesting and subsequent sale of restricted stock units to cover tax obligations.

Craig B. Granowitz, SVP and Chief Medical Officer of Lexicon Pharmaceuticals, exercised stock options and disposed of shares to cover tax obligations on February 28, 2025.

Brian Crum, SVP, General Counsel & Secretary of Lexicon Pharmaceuticals, reports the vesting and subsequent disposal of restricted stock units to cover tax obligations.

Kristen Alexander, VP of Finance and Accounting at Lexicon Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Wendy McDermott, SVP of Human Resources at Lexicon Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Alan J. Main, EVP of Innovation & Chemical Sciences at Lexicon Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Craig B. Granowitz, SVP and Chief Medical Officer of Lexicon Pharmaceuticals, received stock options and restricted stock units on February 13, 2025.

Lisa DeFrancesco, VP of Investor Relations and Corporate Communications at Lexicon Pharmaceuticals, reports acquisition of stock options and restricted stock units.

Brian T. Crum, SVP, General Counsel & Secretary of Lexicon Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Brian Corrigan, SVP of Regulatory & QA at Lexicon Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Scott M. Coiante, SVP and CFO of Lexicon Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Michael Exton, CEO of Lexicon Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Scott M. Coiante, SVP and CFO of Lexicon Pharmaceuticals, acquired 230,000 stock options on January 2, 2025, according to a Form 4 filing with the SEC.

Lexicon Pharmaceuticals director Ivan Cheung acquired 186,685 stock options on December 2, 2024, at an exercise price of $0.8037.

Brian Corrigan, SVP of Regulatory & QA at Lexicon Pharmaceuticals, acquired 200,000 stock options on August 12, 2024.

Jeffrey L. Wade, President and COO of Lexicon Pharmaceuticals, acquired stock options for 307,000 shares on July 8, 2024.

Lexicon Pharmaceuticals' CEO, Michael Exton, reports the acquisition of 1,675,000 stock options with an exercise price of $1.67, vesting over four years.